You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Discontinued Product(R)-4-Carboxy-3-hydroxyphenylglycine (Cat. No. 0319) has been withdrawn from sale for commercial reasons.
Biological Activity for (R)-4-Carboxy-3-hydroxyphenylglycine
Potent NMDA receptor antagonist; weak AMPA/kainate receptor antagonist.
Technical Data for (R)-4-Carboxy-3-hydroxyphenylglycine
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for (R)-4-Carboxy-3-hydroxyphenylglycine
References for (R)-4-Carboxy-3-hydroxyphenylglycine
References are publications that support the biological activity of the product.
Birse et al (1993) Phenylglycine derivatives as new pharmacological tools for investigating the role of metabotropic glutamate receptors in the central nervous system. Neuroscience 52 481 PMID: 7680790
Jones et al (1993) Agonist and antagonist actions of phenylglycine derivatives at depolarization-mediating (1S,3R)-ACPD receptors in neonatal rat motoneurones. Br.J.Pharmacol. 108 86P
Birse et al (1992) Enantiomer specific depressant actions of 4-carboxy-3-hydroxyphenylglycine on mono- and polysynaptic excitation in the isolated newborn rat spinal cord. J.Physiol. 452 185P
View Related Products by Product Action
Keywords: (R)-4-Carboxy-3-hydroxyphenylglycine, (R)-4-Carboxy-3-hydroxyphenylglycine supplier, (R)-4C3HPG, NMDA, Receptors, 0319, Tocris Bioscience
Citations for (R)-4-Carboxy-3-hydroxyphenylglycine
Citations are publications that use Tocris products.
Currently there are no citations for (R)-4-Carboxy-3-hydroxyphenylglycine.
Reviews for (R)-4-Carboxy-3-hydroxyphenylglycine
There are currently no reviews for this product. Be the first to review (R)-4-Carboxy-3-hydroxyphenylglycine and earn rewards!
Have you used (R)-4-Carboxy-3-hydroxyphenylglycine?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Stem Cells
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.